The Pancreatic Cancer Research Team (PCRT) is a division of Translational Drug Development (TD2). PCRT is a consortium of more than 40 clinics worldwide, focused on the rapid development of novel therapeutics for pancreatic cancer.

Founded by thought leaders in pancreatic cancer clinical research, including world-renowned pancreatic cancer experts Dr. Daniel Von Hoff and Dr. Manuel Hidalgo, the consortium is a premiere resource for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer. This network provides the world's most coordinated effort dedicated to rapidly translating research discoveries into new treatments and supportive care.

The main benefits of running a pancreas trial through our group are: access to the world's clinical experts in pancreas cancer; faster patient enrollment (site enrollment that is nearly three times the national average); efficient site start up (on average, the overwhelming majority of PCRT sites can be up and running within 12 to 14 weeks); and experts to provide feedback and guidance for your data and trial design.

Our comprehensive approach includes:

• Strategic design of clinical trials: We seek the best feasibility, effectiveness and overall strategy for drug development.
• Strong relationships with network researchers: Our experienced project managers have strong relationships with PCRT Investigators. PCRT sites enable faster study start-ups and more efficient conduct of ongoing studies.
• An experienced team that can effectively manage all aspects of clinical trials run through the PCRT network, including:
  • Turnkey trial management and oversight.
  • Protocol writing.
  • Specific and rapid selection of premiere clinical research sites from the PCRT network, including availability of feasibility information.
  • Management of the study start-up process.
  • Initial and/or complete budget negotiation and contract facilitation.
  • Efficient communication among PCRT sites and project managers, ensuring timely, accurate and complete submission of study data.

The PCRT Serum and DNA Bank

The PCRT Serum and DNA Bank can help identify biomarkers and predict early recurrence of macroscopic disease or recurrent disease. This biobank includes samples collected from hundreds of pancreatic cancer patients and from healthy-normal and healthy-at-risk donors from throughout the world, including clinically annotated data for in-depth analysis. Should samples in requested categories not be available, studies for prospective sample collection can be designed and executed.